WebStudy CRTH258AUS04 (MERLIN) is a 2-year multicenter, randomized, double-masked Phase 3a study to assess the safety and efficacy of bro/ucizumab 6mg q4 week compared to aflibercept 2mg q4 week in patients with neovascular age related macular degeneration (nAMD) with persistent retinal fluid. The http://weblink.carquest.com/acl/?mfgName=RCH&partNumber=DW-K90258

History of Changes for Study: NCT03710564 - ClinicalTrials.gov

WebNovartis CRTH258AUS04 MERLIN: A Multicenter, Randomized, Double-Masked, Phase IIIa Study to Assess Safety and Efficacy of Brolucizumab Compared to Aflibercept in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retinal Fluid. Site Principal Investigator 2024-Present. WebStudy CRTH258AUS04 (MERLIN) is a 2- year. multicenter, randomized, double- masked Phase 3a study to assess the safety and efficacy of brolucizumab 6mg q4 week compared to aflibercept 2mg q4 week in patients with neovascular age related macular degeneration (nAMD) with persistent retinal fluid. The protection homiris

Clinical Trials - Retina Specialty

WebCRTH258AUS04 Trial Results Summary 3 Brolucizumab is the investigational treatment in this trial. Brolucizumab is an approved treatment in the United States (US) for wet … WebCRTH258AUS04 MERLIN Mar 2024 - Oct 2024. A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of Brolucizumab 6 mg q4 weeks compared with Aflibercept 2 mg q4 weeks ... WebStudy #: CRTH258AUS04 Study Title: A Multicenter, Randomized, Double-Masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 weeks Compared to … residence inn cleveland independence